Medlab Clinical Limited (MDC:ASX)

22.5¢

right-arrow Created with Sketch. 0.015 (7.14%)
MCAP $62.92M
Last trade 16.10pm 27/11/2020 20mins delayed

Latest Announcements

12/11/2020MDCMedlab Clinical Limited
76
MCap
12/11/2020MDCMedlab Clinical Limited
68
MCap
12/11/2020MDCMedlab Clinical Limited
12/11/2020MDCMedlab Clinical Limited
11/11/2020 Price SensitivePSMDCMedlab Clinical Limited
28/10/2020 Price SensitivePSMDCMedlab Clinical Limited
16/10/2020MDCMedlab Clinical Limited
1,246
MCap
16/10/2020MDCMedlab Clinical Limited
254
MCap

Company Overview

Medlab Clinical Limited is engaged in the sale of nutraceutical products and pharmaceutical research. The Company operates through two segments: Nutraceutical and Pharmaceutical Research. Its Manuka-C is scientifically formulated to support optimal immune system function and includes evidence-based ingredients containing a blend of over three ascorbates combined with glutathione and Manuka honey powder. Its NOS NITRIC OXIDE SUPPORT is a pre-exercise sports food containing a selection of evidence-based ingredients combined to support and optimize exercise performance. Its Saccharomyces cerevisiae ssp. boulardii (SB) 5B is a probiotic yeast that helps to maintain gastrointestinal function and integrity by supporting a healthy gut microbial profile; by increasing the production of secretory Immunoglobulin A (sIgA), short-chain fatty acids (SCFAs) and helping to promote the activity of brush border disaccharide enzymes. It also offers Mg Optima and BioClean EPA:DHA + CoQ10.

MDC in the news

Search Previous Announcements